tirzepatide fatty liver disease and The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease Metabolic dysfunction–associated steatotic liver disease
Description
SUSTAIN 7, a clinical trial comparing semaglutide versus dulaglutide, found that gastrointestinal side effects occurred in 43% of participants receiving Ozempic 0.5 mg and 44% receiving Ozempic 1 mg
Schuelke M, Wagner KR, Stolz LE, et al
It specifically refers to the administration of the injection, not the drug itself
PMID: 26132939
Fibroblast growth factorbased pharmacotherapies for the treatment of obesity-related metabolic complications
